Skip to main content
Fig. 1 | Advances in Rheumatology

Fig. 1

From: Compared efficacy of rituximab, abatacept, and tocilizumab in patients with rheumatoid arthritis refractory to methotrexate or TNF inhibitors agents: a systematic review and network meta-analysis

Fig. 1

The Spider chart describes the imbalance among RCTs characteristics included in the meta-analysis according to the non-TNFi treatment used in active arm (ABA, RTX or TCZ). The suffix "_posit.vs.ACR70" represent the independent variables that show positive association with ACR70 response, and the suffix "_neg.vs.ACR70" represent the independent variables that show negative association with ACR70 response. Example: the higher the follow-up time (suffix "_neg.vs. ACR70"), the lower the chance of achieving ACR70 response. Followup.t: follow-up time (total study duration); ACR70: 70% achieving ACR response; ACR50: 50% achieving ACR response; ACR20: 20% achieving ACR response. Background TNFi: percentage of individuals on tumor necrosis factor (TNF) inhibitors; HAQ: Health Assessment Questionnaire score; ABA: abatacept; RTX: rituximab; TCZ: tocilizumab; ACR: American College of Rheumatologists

Back to article page

Advances in Rheumatology

ISSN: 2523-3106